Promising results for Trodelvy, a drug just acquired by Gilead - STAT

Promising results for Trodelvy, a drug just acquired by Gilead - STAT

STAT Plus: Promising results for previously secret cancer drug data that ‘justified’ Gilead Sciences’ $21 billion acquisition

By ADAM FEUERSTEIN

COURTESY IMMUNOMEDICS

Data presented at ESMO show that Trodelvy offers benefits in treating advanced bladder cancer and triple-negative breast cancer.

READ MORE